Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript
Source: SeekingAlpha
2025-12-08 20:37:18 ET
Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies December 8, 2025 6:00 PM EST...
Read the full article on Seeking Alpha
For further details see:
Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript
Assembly Biosciences Inc.
NASDAQ: ASMB
ASMB Trading
-1.93% G/L:
$28.195 Last:
23,015 Volume:
$28.52 Open:
ASMB Latest News
December 22, 2025 08:00:00 am
Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
December 08, 2025 04:05:00 pm
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Re
November 10, 2025 04:05:00 pm
Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
ASMB Stock Data
$431,017,065
8,905,050
58.72%
12
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
